Alport syndrome: facts and opinions
Open Access
- 17 January 2017
- journal article
- review article
- Published by F1000 Research Ltd in F1000Research
- Vol. 6, 50
Abstract
In this commentary, I review recent advances in Alport syndrome genetics, diagnostics, and therapeutics. I also offer some opinions regarding strategies to optimize the early identification of affected individuals to promote early therapeutic intervention.Keywords
This publication has 71 references indexed in Scilit:
- Nanoscale protein architecture of the kidney glomerular basement membraneeLife, 2013
- Safety and Efficacy of the ACE-Inhibitor Ramipril in Alport Syndrome: The Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase III EARLY PRO-TECT Alport Trial in Pediatric PatientsISRN Pediatrics, 2012
- Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research CollaborativePediatric Nephrology, 2012
- Loss of collagen-receptor DDR1 delays renal fibrosis in hereditary type IV collagen diseaseMatrix Biology, 2010
- Genotype–Phenotype Correlation in X-Linked Alport SyndromeJournal of the American Society of Nephrology, 2010
- Stem Cell Therapies Benefit Alport SyndromeJournal of the American Society of Nephrology, 2009
- Bone-marrow-derived stem cells repair basement membrane collagen defects and reverse genetic kidney diseaseProceedings of the National Academy of Sciences, 2006
- Glomerular Expression of Type IV Collagen Chains in Normal and X-Linked Alport Syndrome KidneysThe American Journal of Pathology, 2000
- Distribution of the α1 and α2 chains of collagen IV and of collagens V and VI in Alport syndromeKidney International, 1992
- Thin-Basement-Membrane Nephropathy in Adults with Persistent HematuriaNew England Journal of Medicine, 1989